B. Riley Has Positive Outlook of ARWR FY2026 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Investment analysts at B. Riley increased their FY2026 earnings estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Tuesday, October 21st. B. Riley analyst M. El-Saadi now expects that the biotechnology company will post earnings per share of ($1.02) for the year, up from their previous forecast of ($3.16). B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

A number of other brokerages also recently issued reports on ARWR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Friday. Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. Royal Bank Of Canada reduced their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 18th. Finally, TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $38.00 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The company has a market cap of $5.25 billion, a P/E ratio of -29.69 and a beta of 1.13. The firm’s fifty day moving average is $30.59 and its two-hundred day moving average is $20.73. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $40.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the prior year, the company posted ($1.38) EPS.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the transaction, the insider directly owned 212,122 shares of the company’s stock, valued at approximately $7,424,270. The trade was a 8.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 60,000 shares of company stock valued at $1,725,000. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. CWM LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 6.7% during the 3rd quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock worth $420,000 after purchasing an additional 764 shares during the period. Oak Ridge Investments LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 2.5% during the 1st quarter. Oak Ridge Investments LLC now owns 33,734 shares of the biotechnology company’s stock worth $430,000 after purchasing an additional 823 shares during the period. Resona Asset Management Co. Ltd. boosted its stake in shares of Arrowhead Pharmaceuticals by 8.7% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company’s stock worth $180,000 after purchasing an additional 900 shares during the period. Salomon & Ludwin LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $34,000. Finally, Empowered Funds LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 979 shares during the period. 62.61% of the stock is owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.